Vycor Announces Completion of Software Development of NovaVision's Web Deliverable VRT
ACCESS Newswire
BOCA RATON, FL / ACCESSWIRE / March 16, 2015 / Vycor Medical, Inc. ("Vycor") (VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced the development completion of its web delivered Vision Restoration Therapy (VRT) therapy. The Company has re-engineered its VRT to enable it for direct-to-patient internet delivery and to streamline a number of business processes related to the delivery and servicing of patients; the therapy itself has remained unchanged. The Company further confirmed that the internet-based program was on track to be commercially launched during the second quarter of 2015 and will replace the Company's current "prototype hardware centric" model. For an overview of NovaVision see NovaVision Video.
Commenting on the Company's announcement, Peter Zachariou, CEO of Vycor, stated, "This is an important milestone for the Company. We have now successfully completed the development of both our internet-based NeuroEyeCoach(TM) eye-training program and now our new web deliverable VRT. This now means that we will be able to offer the substantial numbers of people who suffer vision loss as a result of neurological brain damage a cost effective and complete therapy solution. This also represents the final step in moving NovaVision from being a development company to one focused on commercializing its unique suite of products."
There are approximately 8m stroke survivors in the U.S. with 795,000 strokes a year, and approximately 1.5m suffering some sort of traumatic brain injury annually. Up to 30% of these suffer a resultant visual impairment, up to 20% permanently. NovaVision provides a suite of therapies designed to restore and compensate for this vision disability.
VRT is a prescription product and the only FDA cleared therapy (510k) for the restoration of vision loss from neurological damage. VRT is supported by 15 years of clinical research and over 20 studies including a 302 patient study in which notable improvements were seen in 70% of the patients, which is consistent with the Company's experience. Management had previously announced the completion of its new eye-training program NeuroEyeCoach, designed to increase the efficiency of eye movement and re-train the patients' ability to integrate visual information between the left and right hand side. NeuroEyeCoach is also supported by several decades of clinical research and studies and has FDA registration.
The two therapies address two key visual disabilities that result from neurologically-induced vision loss and enable a significant positive impact in a patient's interaction with their environment and hence their ability to successfully perform their daily living activities. NovaVision will be offering VRT and NeuroEyeCoach in one internet-delivered therapy suite creating the most robust, affordable and complete visual therapy solution targeted at neurologically induced vision loss.
About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. ("Vycor") is a publicly traded company (VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue.
Vycor Medical's ViewSite(TM) Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Canada, China, Europe (EU - Class III), Korea and Japan and is seeking or has partial regulatory approvals in Brazil, India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical's VBAS see VBAS Video.
NovaVision develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments. The company's proprietary Visual Restoration Therapy(R) (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury ("TBI"), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at the restoration of vision for neurologically induced vision loss and can be prescribed by any Physician. VRT also has CE Marking for the EU. NovaVision also provides Neuro Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity deep within the field defect.
The Company has also developed a therapy called NeuroEyeCoach(TM). The NeuroEyeCoach(TM) therapy is highly complementary to VRT(TM). The two therapies address different visual disabilities each of which results from neurologically-induced vision loss - a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT provides partial restoration of the patient's lost visual field; NeuroEyeCoach(TM) is designed to increase the efficiency of eye movement and re-train the patients' ability to integrate visual information between the left and right hand side. For an overview of NovaVision see NovaVision Video.
